A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Conditions: Beta-Thalassemia Major Interventions: Genetic: CS-101 injection Sponsors: CorrectSequence Therapeutics Co., Ltd Not yet recruiting

Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials